EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Proline variants in the BRCA1 coiled‐coil domain disrupt folding and binding to PALB2

Chrissy N S Baker, Precious Grace C Pajela, Davis E Martin, Sergei V Dzyuba, Mikaela D Stewart iD

Protein Science · 2025

DOI: 10.1002/pro.5240 ↗

At a glance

Journal article in Protein Science, 2025. Written by Chrissy N S Baker and 4 co-authors. Institution: Department of Biology, Texas Christian University, Fort Worth, Texas, USA. Major MEDLINE topics: Fanconi Anemia Complementation Group N Protein, BRCA1 Protein. Cited 3 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIGMS NIH HHS, Texas Christian University, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Inherited mutations in the genes coding for the tumor suppressor proteins BRCA1 and PALB2 can lead to increased risk of breast and ovarian cancer. Upon DNA damage, these two proteins form a complex to promote double‐stranded break repair via homologous recombination. Missense mutations in either BRCA1 or PALB2 that disrupt this important interaction result in loss of effective DNA damage repair and are associated with breast tumorigenesis. However, the overwhelming majority of missense mutations found in the binding domains of these two genes remain classified as variants of unknown significance. Here we report an in vitro assay for assessing the effect of variants of unknown significance on the heterodimerization of PALB2 and BRCA1 that recapitulates the effect of the known deleterious mutations. We apply the assay to several variants of unknown significance in BRCA1 which reveals other mutations in this region that also disrupt binding, including a mutation of a residue not predicted to directly interact with PALB2. Structural analysis indicates that all BRCA1 mutations to proline tested disrupt α‐helix formation and therefore are not well tolerated even when located at positions outside of the PALB2‐binding interface. This assay and the structural hypothesis described will be helpful for assessing risk for variants identified in the future in the BRCA1/PALB2 interaction domains.

Subjects

MeSH terms (MEDLINE)

Fanconi Anemia Complementation Group N ProteinBRCA1 ProteinHumansProtein BindingProlineProtein FoldingMutation, MissenseProtein DomainsModels, Molecular

Author keywords

BRCA1PALB2circular dichroismcoiled‐coil domainsisothermal titration calorimetryprotein–protein interactionvariants of unknown significance

Substances

Fanconi Anemia Complementation Group N ProteinBRCA1 ProteinPALB2 protein, humanBRCA1 protein, humanProline

Authors and institutions

  • Department of Biology, Texas Christian University, Fort Worth, Texas, USA.
  • Department of Chemistry and Biochemistry, Texas Christian University, Fort Worth, Texas, USA.

ORCID profiles: Mikaela D Stewart

Funding

  • NIGMS NIH HHS
  • Texas Christian University
  • NIH HHS
  • National Institutes of Health

Cite

APA

Baker, C. N. S., Pajela, P. G. C., Martin, D. E., Dzyuba, S. V., & Stewart, M. D. (2025). Proline variants in the BRCA1 coiled‐coil domain disrupt folding and binding to PALB2. Protein Science. https://doi.org/10.1002/pro.5240

Vancouver

Baker CNS, Pajela PGC, Martin DE, Dzyuba SV, Stewart MD. Proline variants in the BRCA1 coiled‐coil domain disrupt folding and binding to PALB2. Protein Science. 2025. doi:10.1002/pro.5240

BibTeX
@article{Baker2025,
  author = {Baker, Chrissy N S and Pajela, Precious Grace C and Martin, Davis E and Dzyuba, Sergei V and Stewart, Mikaela D},
  title = {Proline variants in the BRCA1 coiled‐coil domain disrupt folding and binding to PALB2},
  journal = {Protein Science},
  year = {2025},
  doi = {10.1002/pro.5240}
}
Start for free →